Zeroing In: Ending the HIV Epidemic Grant Program
Forecasted
Gilead Sciences' Zeroing In: Ending the HIV Epidemic Grant Program funds innovative, community-based research and digital solutions to advance HIV prevention and care globally.
Funder: Gilead Sciences
Due Dates (Anticipated): October 2026
Funding Amounts: $24 million awarded to date; typical award size and duration varies by project and region.
Summary: Supports community-driven projects advancing HIV prevention, care, and digital health innovation for populations most affected by HIV globally.
Description
The Zeroing In: Ending the HIV Epidemic Grant Program, funded by Gilead Sciences, is dedicated to supporting organizations working to improve the health and wellness of communities most impacted by HIV worldwide. The program emphasizes the importance of community-based and grassroots organizations in delivering high-quality HIV prevention and care services. Funded projects may include local community programming, multi-organization collaborations, and coalition-led efforts that align with established international and country-specific goals to end the HIV epidemic.
The initiative focuses on three main areas:
- Digital Health Innovations: Projects that create or enhance technology infrastructure, or develop digital outreach strategies to reach key populations.
- Community Outreach and Education: Innovative community engagement and education efforts aimed at empowering and informing populations requiring greater health support.
- Comprehensive HIV Innovation Programs: Initiatives such as non-clinical testing, supportive services, and biomedical prevention options.
Since its inception, the program has awarded $24 million in grants to projects addressing health disparities, improving healthcare access, advancing medical education, and supporting communities most affected by HIV.
